Study Objectives

The REVEAL Registry has been carefully designed to be a broad-based, observational study of patients in the United States with WHO Group I PAH. The study is intended to generate new hypotheses and understandings of the clinical course of patients with PAH and which treatments produce the best outcomes for patients with different underlying forms of the disease.

The objectives of the REVEAL Registry are outlined as follows:

• To characterize the demographics and clinical course of the patient population diagnosed with WHO Group I PAH
• To evaluate differences in patient outcomes according to WHO Group I classification subgroup
• To compare patient outcomes in patients who do and do not meet prespecified hemodynamic criteria for the diagnosis of PAH
• To identify clinical predictors of short-term and long-term outcomes
• To assess the relationship between PAH medications, individually and in combination, and patient outcomes
• To report temporal trends in treatments and outcomes for newly diagnosed patients
• To collect timely and relevant data that will assist in the evolving research needs of the PAH community